Abstract: A fabric cleaning composition comprising from 1% to 20% by weight of the fabric cleaning composition of an oxygen-based bleaching source and a hueing agent, and wherein the neat composition has a pH between 2.5 and 5.5, and a method of using said fabric cleaning composition.

Abstract: This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions.

Abstract: The present invention relates to compounds for and a method of detecting beta-lactamase activity in a sample. The sample is contacted with a nanoparticulate tag. The nanoparticulate tag comprises a metal or a combination of metals, or it comprises a nanotube of a metal, boron nitride and/or carbon. The respective metal is capable of forming one of a covalent bond, a coordinative bond and a non-covalent interaction with a thio or a seleno group. The sample is contacted with a compound of one of general formulas (I)-(III) and (VII)-(IX). At least one beta-lactam moiety of the compound is cleaved by the beta-lactamase activity in the sample. As a result a cleavage moiety Z-A-Z, Z-A-Z—R15, Z-A-Z—R16, Z-A-Z—R17, Z-A-Z—R18 or Z-G-N(R8)R9 is released that is immobilised on the surface of the nanoparticulate tag by a covalent bond via a Z atom. The presence of beta-lactamase activity is determined based on the presence of the cleavage moiety immobilized onto the surface of the nanoparticulate tag.

Abstract: Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as ?-lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of ?-lactamases. These compounds restore/potentiate the activities of ?-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting ?-lactamases.

Abstract: Inhibitors of the enzyme beta-lactamase of formula (I): are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.

Abstract: The present invention provides a method by which a 6-hydroxyethyl penam compound represented by General Formula (2) below can be produced with a high selectivity: wherein R represents a hydrogen atom or a protective group for carboxylic acid and X2 represents a halogen atom; the method including the steps of reacting a Grignard reagent with a halogeno penam compound represented by General Formula (1) below: wherein R and X2 are the same as above, and X1 represents a halogen atom; reacting the generated compound with an amine compound; and further reacting the generated compound with acetaldehyde.

Abstract: The present invention is related to processes for the preparation of faropenem, which comprises treating the compound of Formula II, with an alkali metal salt of a substituted or unsubstituted C5-10 carboxylic acid and a catalytic amount of a palladium complex in the presence of an organic solvent, followed by the treatment of the reaction mixture of with water and a water miscible solvent, and isolating a hydrate of an alkali metal salt of faropenem from the reaction mass, wherein water is not removed from the reaction mixture in water treatment or isolation steps.

Abstract: Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.

Abstract: Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.

Abstract: An object of the invention is to provide an industrially advantageous process capable of remarkably suppressing the generation of an undesirable by-product cepham compound to thereby efficiently produce a desired 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylic acid ester. In the present invention, a diphenylmethyl 2?-bromomethyl-2?-methylpenam-3?-carboxylate (BMPB) is reacted with 1,2,3-triazole in a halogenated hydrocarbon solvent at ?5° C. or lower. The reaction in a halogenated hydrocarbon solvent at ?5° C. or less can remarkably suppress the generation of an undesirable by-product cepham compound, so that the desired diphenylmethyl 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylate (TMPB) can be efficiently produced.

Abstract: The present invention provides a method by which a 6-hydroxyethyl penam compound represented by General Formula (2) below can be produced with a high selectivity: wherein R represents a hydrogen atom or a protective group for carboxylic acid and X2 represents a halogen atom; the method including the steps of reacting a Grignard reagent with a halogeno penam compound represented by General Formula (1) below: wherein R and X2 are the same as above, and X1 represents a halogen atom; reacting the generated compound with an amine compound; and further reacting the generated compound with acetaldehyde.

Abstract: The present invention provides 2?-chloromethyl-2?-methylpenam-3?-carboxylic acid benzhydryl ester (CMPB) crystals of excellent stability, and a process for producing the CMPB crystals comprising the steps of (A) concentrating a solution containing CMPB; (b) subjecting the thus-obtained concentrate to column chromatography; (C) concentrating a CMPB-containing fraction; and (D) dissolving the thus-obtained CMPB-containing concentrate in an ether solvent and adding a hydrocarbon solvent to the resulting solution to precipitate CMPB crystals.

Abstract: The present invention provides anhydrous crystals of ?-lactam compound represented by the formula: The ?-lactam compound of the invention is produced by heating an aqueous solution of a salt of the ?-lactam compound and adjusting the pH of the aqueous solution to 3 or lower. The ?-lactam compound has excellent storage stability.

Abstract: Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.

Abstract: The present invention provides solid form of faropenem free acid, its hydrates and processes for their preparation thereof. Thus, for example, dissolving an alkali metal salt of faropenem in water, adjusting the pH of the solution formed with an acid to below about 2.5 and collecting the precipitated solid to obtain solid faropenem free acid.

Abstract: The present invention relates to compounds for and a method of detecting beta-lactamase activity in a sample. The sample is contacted with a nanoparticulate tag. The nanoparticulate tag comprises a metal or a combination of metals, or it comprises a nanotube of a metal, boron nitride and/or carbon. The respective metal is capable of forming one of a covalent bond, a coordinative bond and a non-covalent interaction with a thio or a seleno group. The sample is contacted with a compound of one of general formulas (I)-(III) and (VII)-(IX). At least one beta-lactam moiety of the compound is cleaved by the beta-lactamase activity in the sample. As a result a cleavage moiety Z-A-Z, Z-A-Z-R15, Z-A-Z-R16, Z-A-Z-R17, Z-A-Z-R18 or Z-G-N(R8)R9 is released that is immobilised on the surface of the nanoparticulate tag by a covalent bond via a Z atom. The presence of beta-lactamase activity is determined based on the presence of the cleavage moiety immobilized onto the surface of the nanoparticulate tag.

Abstract: The present invention provides anhydrous crystals of ?-lactam compound represented by the formula: The ?-lactam compound of the invention is produced by heating an aqueous solution of a salt of the ?-lactam compound and adjusting the pH of the aqueous solution to 3 or lower. The ?-lactam compound has excellent storage stability.

Abstract: The present invention provides novel 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylic acid benzhydryl ester (TMPB)-acetone crystals for use in the production of 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylic acid 1,1-dioxide benzhydryl ester (TAZB); a process for producing the TMPB-acetone crystals comprising the steps of (A) concentrating a TMPB-containing organic solvent solution, (B) dissolving the resulting concentrate in acetone, and (C) precipitating TMPB-acetone crystals from the acetone solution thus obtained; and a process for producing TAZB comprising the step of reacting the TMPB-acetone crystals with an oxidizing agent.

Abstract: A process for preparing a penicillanic acid compound of the formula (2) comprising reacting a halogenated penicillanic acid compound of the formula (1), (a) in the presence of a metal bismuth or bismuth compound, (b) with a metal having a lower standard oxidation-reduction potential than bismuth to obtain the compound (2) (X and Y are a hydrogen atom or halogen atom, provided that X and Y are not hydrogen atoms at the same time, n is an integer of 0 to 2, R is carboxylic acid protecting group) (n and R are same as above).

Abstract: The present application describes deuterium-enriched tazobactam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof preparation thereof formulation thereof and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.

Abstract: The present invention is related to processes for the preparation of faropenem.

Abstract: An object of the invention is to provide an industrially advantageous process capable of remarkably suppressing the generation of an undesirable by-product cepham compound to thereby efficiently produce a desired 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylic acid ester. In the present invention, a diphenylmethyl 2?-bromomethyl-2?-methylpenam-3?-carboxylate (BMPB) is reacted with 1,2,3-triazole in a halogenated hydrocarbon solvent at ?5° C. or lower. The reaction in a halogenated hydrocarbon solvent at ?5° C. or less can remarkably suppress the generation of an undesirable by-product cepham compound, so that the desired diphenylmethyl 2?-methyl-2?-[(1,2,3-triazol-1-yl)methyl]penam-3?-carboxylate (TMPB) can be efficiently produced.

Abstract: The present invention provides a method for preparing a ?-lactam compound of the following Formula (3), which comprises the step of reacting a compound of the following Formula (1) with a trialkyl phosphite represented by the formula (R5O)3P (wherein R5 represents an ethyl group, etc.) in an amount of 2 to 5 moles per mole of the compound and the step of heating the resulting reaction mixture in a diluent, wherein said method is characterized by having the step of completely removing unreacted trialkyl phosphite from the reaction mixture prior to the step of heating. (wherein X represents S, etc., Y represents N, etc., n represents 0 or 1, R1 represents an optionally substituted alkyl group containing 1 to 10 carbon atoms, etc., R2 and R3 each represent an optionally substituted alkyl or heterocyclic group, etc., and R4 represents an alkenyloxy group containing 1 to 6 carbon atoms, etc., provided that R1 and R2 may together form a ?-lactam ring, etc.

Abstract: An improved process for the purification of tazobactam or its derivatives of the formula (I) wherein R represents hydrogen, C1-C6alkyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, o-chlorobenzyl, benzyl or diphenylmethyl, which comprises the steps of: i) slurrying the compound of formula (I) containing the impurity of the formula (V) using a solvent in the presence or absence of tartaric acid with or without the presence of water at 20-50° C. and ii) isolating the compound of formula (I) in pure form.

Abstract: The invention relates to prodrugs of sulopenem of formula (I): wherein R1 is —(C2-C8)alkyl, or a solvate or hydrate thereof. The invention also relates to the preparation, formulation, and use of the prodrugs of sulopenem to treat a disorder such as an infection in a patient in need thereof.

Abstract: The present invention provides a method for preparing an organic compound, which comprises a dehydration step of distilling off water from a polar organic solvent solution containing the organic compound and water to bring the concentration of water below a given level, wherein the dehydration step comprises distilling off water together with the polar organic solvent while adding a polar organic solvent to the solution, or comprises repeating several cycles of adding a polar organic solvent to the solution and then distilling off water together with the polar organic solvent. The present invention further provides the preparation of an organic compound, which enables efficient isolation of the target product in high isolated yield from a polar organic solvent solution containing the organic compound, water and, if necessary, a compound which produces, upon coming into contact with water or the like, a substance accelerating the decomposition of the organic compound.

Abstract: A process for the preparation of 3-methylcepham-4-carboxylate of the formula (I). wherein R2 and R3 may be same or different and represent hydrogen, halogen, amino, alkyl, phenacetamido, substituted acetamido, phthalimido with a proviso that both R2 and R3 are not NH2, phenacetamido, phthalimido and the like; R1 represents a lower alkyl, p-methoxybenzyl, p-nitrobenzyl, o-nitrobenzyl, o-methoxybenzyl, o-chlorobenzyl or diphenylmethyl group, or a suitable ester residue which can be deprotected at a latter stage, L represents a leaving group; which comprises cyclizing the compound of formula (III) using a cyclizing agent in the presence of organic or inorganic nitrites and a solvent at a temperature in the range of ?40° C. to +60° C. to obtain compound of formula (I).

Abstract: Compounds of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting ?-lactamase enzymes, for enhancing the activity of ?-lactam antibiotics, and for treating ?-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

Abstract: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X is S.

Abstract: Prodrugs of 6-?-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention or a solvate thereof, an optional beta-lactam antibiotic and a pharmaceutically acceptable excipient. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.

Abstract: Compounds of formula (I): wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting simultaneously serine and metallo-?-lactamase enzymes, for enhancing the activity of ?-lactam antibiotics, and for treating ?-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

Abstract: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B denotes hydrogen and the other an optionally substituted fused tricyclic heteroaryl group; and X is S.

Abstract: The present invention relates to a process for preparing 2?-methyl-2?-substituted methyl penam derivatives from cepham derivatives, more particularly the present invention provides a novel process for preparing 2?-heterocyclyl methyl penam derivatives of the formula (I) by reacting a cepham compound with a heterocylic amine to form an intermediate compound, and oxidizing the intermediate compound to produce the 2?-heterocyclyl methyl penam derivatives of the formula (I), wherein R1 represents carboxylic acid protecting group; R2 and R3 may be same or different and independently represent hydrogen, halogen, NH2, acylamino, phthalimido with a proviso that both R2 and R3 are not NH2, acylamino, phthalimido; Het represents a 5 or 6 membered nitrogen containing heterocycle ring system having one or more heteroatoms selected from O, S, or N.

Abstract: Compound of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting &bgr;-lactamase enzymes, for enhancing the activity of &bgr;-lactam antibiotics, and for treating &bgr;-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.

Abstract: The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease.

Abstract: The present invention provides a compound of formula 1, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

Abstract: The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease.

Abstract: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.

Abstract: The crystal of the invention is crystal of diphenylmethyl 2-methyl-2-triazolylmethylpenam-3-carboxylate which is stable substantially without decomposition or degradation of properties even when left to stand at room temperature for 1 year. The crystal of the invention can be prepared by a process comprising the steps of concentrating a solution containing diphenylmethyl 2-methyl-2-triazolylmethylpenam-3-carboxylate represented by the formula (2) wherein Ph is a phenyl group, diluting the concentrate with acetic ester and mixing the diluted solution with hexane or a solvent mixture of hexane and acetic ester to crystallize the diphenylmethyl 2-methyl-2-triazolylmethylpenam-3-carboxylate.

Abstract: Compounds of formula (I) in which: R1 is hydrogen or an organic substituent group; R2 is a fused bicyclic heterocyclic ring system of general formula (a) wherein R4 and R5 are independently hydrogen or one or more substituents replacing hydrogen atoms in the ring system shown; m is 2 or 3; p is 0, 1 or 2; and R3 is hydrogen, a salt-forming cation or an ester-forming group; and the symbol ═/═ indicates that the double bond may be in either the E or Z configuration.

Abstract: Compounds of the formula and the salts, esters and amides thereof wherein Z is S, SO, SO2 or O; each of R1, R2 and R3 is independently H or substituted or unsubstituted alkyl (1-10C), substituted or unsubstituted alkenyl, substituted or unsubstituted acyl (2-11C), substituted or unsubstituted aryl (6-14C), substituted or unsubstituted arylcarbonyl (7-15C), substituted or unsubstituted arylalkyl (7-15C), substituted or unsubstituted pyridyl wherein substituents on any alkyl, alkenyl, or acyl moiety are selected from the group consisting of halo, and RO, wherein R is H or alkyl (1-6C), and substituents on any aryl or pyridyl moiety are selected from the group consisting of halo, and RO, where R is H or alkyl (1-6C), —CN and —CF3; with the proviso that R1 is not H and R1 and R3 are not identical and with the proviso that in formula (1), the B ring may contain one double bond that is located between positions 2 and 3, and in formula (2), the B ring may contain one double bond tha

Abstract: Processes for preparing compounds having two or three antibiotic functionalities using quinolone derivatives, &bgr;-lactams and vancomycin and the like as the starting materials and chloride linking agents; and the novel compounds prepared by these processes, are disclosed.

Abstract: Compounds are provided having the following formulae I and II: wherein n is 0 or 1 and when n=1, R is a 5 or 6 membered heterocyclic ring, hydroxy, halogen, oxo, carbamoyl, alkoxy, or disubstituted amino, when n=0, R is an ester, cyano or amide group; X is CH or NH; R3 is cyano, methoxy, or acetamido; R1 is hydrogen, alkyl, a negative charge, a cation selected from the group consisting of sodium, potassium and tetraalkylammonium and acyloxyalkyl, or alkoxycarbonyloxyalkyl; and R2 is hydrogen, acyl, trisubstituted silyl carbamoyl or an amino acid residue; or pharmaceutically acceptable salts thereof.

Abstract: The present invention is directed to a process for preparing an exo-methylenepenam compound wherein a cephem compound is reduced with a metal having a standard oxidation-reduction potential of up to −0.3 (V/SCE) in an amount of at least one mole per mole of the cephem compound and with a metal compound having a higher standard oxidation reduction potential than the metal and in an amount of 0.

Abstract: Compound of formula I: 1

Abstract: A process for preparing halogenated &bgr;-lactam compounds, characterized in that a &bgr;-lactam amino compound of the formula (1) is reacted with nitrous acid or nitrite in a slurry dispersion state in water, under acid condition in the presence of halogen molecules, thereby obtaining a halogenated &bgr;-lactam compound of the formula (4) wherein n is an integer of 0 to 2; A is the formula (2) or (3); R1 and R2 are the same or different and are hydrogen atom, halogen atom, C1˜C3 alkyl group, C2˜C4 alkenyl group, C2˜C4 alkynyl group, nucleophilic group, or CH2R3; and R3 is halogen atom or nucleophilic group  wherein A is as defined above; X1 is hydrogen atom or halogen atom; and X2 is halogen atom.

Abstract: The present invention relates to penem antibacterial agents in which the releaseable liphophilic aromatic side-chain, tethered to the carbapenem nucleus via a methylene linker, necessary for anti-MRSA activity replaces the non-releaseable liphophilic side-chains found in 2-aryl and 2-benzothiazolylthio carbapenem compounds. The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: Pharmaceutical compositions and methods of use are also included.

Abstract: A method for preparing an &agr;-oxolactam comprising, reacting a corresponding &agr;-diazolactam with an oxygen donor, in the presence of a transition metal catalyst, to yield the corresponding &agr;-oxolactam.

Abstract: Procedure for the preparation of dioxopenicillanic acid derivatives and its salts pharmaceutically acceptable with general formula I, where, R is hydrogen, alkyl group containing 1 to 5 Carbon atoms or a residue of type --CH2R', where R' is hydrogen, halogen or a p-toluensulfonyl group. These are prepared by treatment of the compounds of general formula II, where R is as previously defined and X may be hydrogen or bromine, with a metallic reagent constituted by a mixture or alloy of copper and/or cobalt and/or manganese with iron and/or nickel in an aqueous/organic medium.These compounds are useful as inhibitors of beta-lactamase.